Advertisement
Organisation › Details
AB2 Bio S.A.
AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs. Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 - MAS, Adult onset Still's Disease, Chronic Obstructive Pulmonary Disease and many others. AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases. Extensive Phase I and Ib clinical trials demonstrated a high tolerance and an excellent safety profile of our drug. We have advanced clinical programs in NLRC4 – MAS and in Adult onset Still’s Disease. *
Start | 2010-01-01 established | |
Industry | tadekinig alfa (IL-18BP – Interleukin-18 Binding Protein) | |
Industry 2 | drug development | |
Person | Sleight, Andrew (AB2 Bio 201602 CEO before 21y at Roche) | |
Person 2 | Cunha, Fernando (AB2 Bio 201602 CFO) | |
Region | Lausanne VD | |
Country | Switzerland | |
Street | EPFL Innovation Park EPFL Innovation Park, Bldg. B, 4th Floor | |
City | 1015 Lausanne VD | |
Tel | +41-21-693-8280 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
�About Section� taken from web site of organisation on 22.02. | ||
Record changed: 2023-07-10 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top